CDNA vs TVTX
CareDx, Inc vs Travere Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TVTX
Travere Therapeutics, Inc.
67
Buy
| Metric | CDNA | TVTX |
| AI Score |
67
|
67
|
| Price |
$45.31
|
$62.07
|
| P/E Ratio |
21.06×
|
-138.09×
|
| ROE |
-7.0%
|
-22.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.6%
|
94.4%
|
| Debt / Equity |
0.05×
|
25.16×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
74.8
|
64.5
|
| Beta |
2.419
|
1.042
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for CDNA versus TVTX.
The committee scores are tied.
CDNA and TVTX both score 67/100.
CDNA Committee View
83% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is bollinger bandwidth of 45.6% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 32.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 227.0% YoY — Growth
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 75 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
TVTX Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 19.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 19.4% signals elevated volatility — Risk